<DOC>
	<DOCNO>NCT01135394</DOCNO>
	<brief_summary>The purpose study determine predictor response pioglitazone , anti-diabetic medication . The investigator know randomize clinical trial 30 % patient respond type medication . There presently way identify group patient lead unnecessary drug exposure medication cost .</brief_summary>
	<brief_title>Pharmacogenomics Thiazolidinediones</brief_title>
	<detailed_description>In phase I , subject eligible base height weight general health information sign inform consent . In phase II , subject screen ensure fit inclusion/exclusion criterion , include oral glucose tolerance test . Other blood test perform check complete blood count , lipid , liver function electrolyte . Qualifying volunteer enter phase III , consist outpatient radioimaging body composition , metabolic testing ( intravenous glucose tolerance test ) , tissue biopsy . Blood also draw genetic test microarray study leukocytes . Written medication information instruction pioglitazone , discharge instruction satisfaction survey follow tissue biopsy procedure give subject study . During phase IV , subject begin pioglitazone therapy . Every 4 week throughout drug intervention , glycemic control , lipoprotein profile , weight monitor . After 12 week pioglitazone therapy , X-ray MR measurement body composition , biopsies metabolic test perform phase III repeat ( phase V ) , blood drawn microarray study leukocytes . Thereafter , subject option enrol 10 week , behavioral weight loss program ( phase VI ) . Following 10-week weight loss program , outcome measurement repeat ( phase VII ) . Throughout study , Women Child Bearing Potential ( WCBP ) HCG urine pregnancy test . Pregnancy test perform Women childbearing potential , meaning woman pre-menopausal surgical sterilization . Women hysterectomy tubal ligation least six month prior sign inform consent postmenopausal least one year , instruct practice one follow method birth control throughout study : oral , transdermal , implantable hormonal contraceptive , intrauterine device , diaphragm plus spermicide , condom plus spermicide , abstinence . Pioglitazone may reduce effectiveness hormonal type contraceptive . Women use hormonal method birth control advise use barrier method well . Female subject inform notify investigator immediately think might become pregnant study . Participants eligible 10 visit approximate 15-week period . Participants choose participate optional weight management program additional 10 week treatment final visit .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>Age 3564 BMI : ≥ 25 ≤ 40 Pregnancy determine urine pregnancy test Breastfeeding , plan become pregnant study Physical dimension exceed limit equipment use Stage III great congestive heart failure Symptomatic peripheral vascular disease Stroke Severe hypertension ( &gt; 170/100 mmHg ) Anemia ( Hgb Hct &lt; normal reference range ) Receiving treatment thyroid , pituitary , kidney liver disease ( except control thyroid hormone replacement ) History diabetes ( told doctor , take diabetic medication Fasting glucose value diagnostic diabetes 2h oral glucose tolerance test diagnostic diabetes Rheumatoid arthritis History wrist , hip leg fracture age 45 History kidney stone Medications investigator judge make interpretation result difficult increase risk participation ( e.g . anticoagulant ) Any disease condition investigator judge affect bone metabolism make interpretation result difficult increase risk participation ( e.g . anemia , cardiac decompensation , intolerance pioglitazone , lidocaine , agent use )</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Pioglitazone</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Healthy adult</keyword>
	<keyword>Thiazolidinediones</keyword>
	<keyword>Pharmacogenetics</keyword>
</DOC>